https://sms.carm.es/ricsmur/handle/123456789/17165 2026-04-04T01:55:44Z 2026-04-04T01:55:44Z Pascual-Morena, Carlos Garrido-Miguel, Miriam Martínez-García, Irene Luceron-Lucas-Torres, Maribel Rodríguez-Gutiérrez, Eva Berlanga-Macias, Carlos Fernández-Bravo-Rodrigo, Jaime Patino-Cardona, Silvana https://sms.carm.es/ricsmur/handle/123456789/25128 2026-03-09T09:02:20Z 2025-05-10T00:00:00Z

Association of Dietary Advanced Glycation End Products with Overall and Site-Specific Cancer Risk and Mortality: A Systematic Review and Meta-Analysis Pascual-Morena, Carlos; Garrido-Miguel, Miriam; Martínez-García, Irene; Luceron-Lucas-Torres, Maribel; Rodríguez-Gutiérrez, Eva; Berlanga-Macias, Carlos; Fernández-Bravo-Rodrigo, Jaime; Patino-Cardona, Silvana Background/Objectives: Dietary advanced glycation end products (dAGEs) have a pro-inflammatory effect and increase oxidative stress, potentially leading to cancer. The aim of this study was to estimate the association between dAGEs consumption and risk and mortality from overall cancer and according to its site. Methods: A systematic search was conducted in Medline, Scopus, Web of Science, and the Cochrane Library from inception to April 2025. The search strategy was conducted according to the PECO structure adapted to this study, as well as the inclusion criteria, in which the population (P) was the adult population, the exposure (E) was the highest level of dAGEs intake, the comparator (C) was the lowest level of dAGEs intake, and the outcomes (O) were the overall cancer risk, cancer risk by site, and cancer mortality. Results across studies were summarised using random effects and fixed effects. Results: Fourteen studies were included in the systematic review. In the random-effects meta-analysis, high dAGEs intake was associated with Hazard Ratio (HR) = 0.99 [95% Confidence Interval (95% CI): 0.98, 1.00] for overall cancer risk. However, although there was no association with breast cancer (BC), there was an association with invasive BC, with HR = 1.14 (95% CI: 1.05, 1.23). In contrast, in other tumours, there were opposite results depending on the site of the cancer. Conclusions: The reduction in cancer risk is not clinically significant. However, high consumption of dAGEs may increase the risk of BC, particularly the invasive BC, which is a challenge for cancer prevention and subsequent mortality. Due to the limited evidence, further studies are needed to confirm the potential impact of dAGEs, as well as other dietary factors that may play a larger role in cancer development.

2025-05-10T00:00:00Z Fernández-Bravo-Rodrigo, Jaime Pascual-Morena, Carlos Saz-Lara, Alicia Martínez-García, Irene Lever-Megina, Carla-Geovanna Patino-Cardona, Silvana Flor-García, Amparo Cavero-Redondo, Iván https://sms.carm.es/ricsmur/handle/123456789/24811 2026-03-09T08:58:08Z 2026-01-01T00:00:00Z

Real-world effectiveness and safety of galcanezumab for the treatment of migraine: A systematic review and meta-analysis Fernández-Bravo-Rodrigo, Jaime; Pascual-Morena, Carlos; Saz-Lara, Alicia; Martínez-García, Irene; Lever-Megina, Carla-Geovanna; Patino-Cardona, Silvana; Flor-García, Amparo; Cavero-Redondo, Iván OBJECTIVE: This study aimed to summarize and pool real-world evidence on the clinical effectiveness and safety of galcanezumab. BACKGROUND: Migraine is a disabling primary headache disorder. Several drugs that target calcitonin gene-related peptide, such as galcanezumab, have recently been developed. However, real-world effects have not been well studied. METHODS: A systematic search of PubMed, Scopus, and Web of Science was conducted from inception to February 2025. Studies that estimated the real-world effects of galcanezumab on monthly migraine days (MMDs), monthly headache days (MHDs), Headache Impact Test, Migraine Disability Assessment Scale, number of days in medication, acute monthly intake (AMI), pain intensity, and safety outcomes were included. Meta-analyses of proportions or mean differences were performed. RESULTS: Thirty-six studies were included, with an agreement of 0.93 [95% confidence interval (CI): 0.90, 0.96]. One month after the first injection, the reduction effects were -6.93 days (95% CI: -7.88, -5.99) for MMD, -8.55 days (95% CI: -11.32, -5.78) for MHD, and -7.96 points (95% CI: -8.93, -6.99) for Headache Impact Test. Over 60% of patients achieved a reduction in MMD/MHD of at least 50% within 3 months. The effect increased gradually and slightly up to 12 months. The adverse event rates were 0.25 (95% CI: 0.14, 0.38) and 0.35 (95% CI: 0.27, 0.45) at 6 and 12 months, respectively, with constipation being the most common. CONCLUSION: Galcanezumab appears to be associated with clinically meaningful improvements in migraine and favorable safety outcomes, although the evidence certainty is limited by heterogeneity.

2026-01-01T00:00:00Z Santos-Mateo, Juan-José Gimeno-Blanes, Juan-Ramón https://sms.carm.es/ricsmur/handle/123456789/24372 2026-02-12T12:37:50Z 2018-08-12T00:00:00Z

Alcohol septal ablation in hypertrophic cardiomyopathy Santos-Mateo, Juan-José; Gimeno-Blanes, Juan-Ramón Alcohol septal ablation (ASA) has become an alternative to surgical myectomy in obstructive hypertrophic cardiomyopathy since it was first introduced in 1994 by Sigwart. The procedure alleviates symptoms by producing a limited infarction of the upper interventricular septum, resulting in a decrease in left ventricular outflow tract (LVOT) gradient. The technique has been improved over time and the results are comparable with those of myectomy. Initial concerns about long-term outcomes have been largely resolved. In this review, we discuss indications, technical aspects, clinical results and patient selection to ASA.

2018-08-12T00:00:00Z Gómez-Alarcón, Ana Quesada-Fernández, María-Nieves Parras-Onrubia, Fátima Díaz-Serrano, María-Dolores Quesada-Villar, José Hernández-Aznar, José-Fernando https://sms.carm.es/ricsmur/handle/123456789/24356 2026-02-12T12:37:56Z 2019-08-02T00:00:00Z

Linfoma tipo Burkitt con afectación ovárica como única manifestación inicial: caso clínico y revisión de la literatura Gómez-Alarcón, Ana; Quesada-Fernández, María-Nieves; Parras-Onrubia, Fátima; Díaz-Serrano, María-Dolores; Quesada-Villar, José; Hernández-Aznar, José-Fernando

2019-08-02T00:00:00Z